Safety and immunogenicity of a multidose vial formulation of 13-valent pneumococcal conjugate vaccine administered with routine pediatric vaccines in healthy infants in India: A phase 4, randomized, open-label study
Sanjay Lalwani(Bharati Vidyapeeth Deemed University), Stephen Lockhart(Johns Hopkins University), Suresh Suroju(Pfizer (United Kingdom)), Padmasani Venkat Ramanan(Unknown), Rohit Chand(Myongji University), Amita Sapru, Warren V. Kalina(Pfizer (United States)), Daniel A. Scott(Naval Medical Research Command), Bela H Shah(B.J. Medical College), Meichun Ding(Pfizer (United States)), N. Karthik Nagesh(Manipal Hospital), Dinesh Kaul(Sir Ganga Ram Hospital), Sundaram Balasubramanian(Jawaharlal Nehru Centre for Advanced Scientific Research)
Cited by 7
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k
Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
|New England Journal of Medicine|2015|1.2k